<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385228</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00026577</org_study_id>
    <secondary_id>PZP113296</secondary_id>
    <secondary_id>c09-039</secondary_id>
    <nct_id>NCT01385228</nct_id>
  </id_info>
  <brief_title>Pazopanib, Docetaxel, Prednisone Prostate</brief_title>
  <official_title>Phase I Study of Docetaxel, Prednisone and Pazopanib in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel George, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to define the safety and tolerability of docetaxel/prednisone in&#xD;
      combination with pazopanib (DPP) in men with metastatic Castration Resistant Prostate Cancer&#xD;
      (mCRPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I study will consist of a dose escalation portion which includes a dose escalation&#xD;
      phase of 10 dose levels: (1a) docetaxel 60 mg/m2, pazopanib 400 mg daily, prednisone 5 mg&#xD;
      BID; (2a) docetaxel 75 mg/m2, pazopanib 400 mg daily, prednisone 5 mg BID; and (3a) docetaxel&#xD;
      75 mg/m2, pazopanib 600 mg daily, prednisone 5 mg BID; (4a) docetaxel 75mg/m2, pazopanib 800&#xD;
      mg daily, (5a) docetaxel 75mg/m2, pazopanib 1000mg daily, prednisone 5 mg; (1b) docetaxel 60&#xD;
      mg/m2, pazopanib 400 mg daily x 17 days, prednisone 5 mg BID; (2b) docetaxel 75 mg/m2,&#xD;
      pazopanib 400 mg daily x 17 days, prednisone 5 mg BID; and (3b) docetaxel 75 mg/m2, pazopanib&#xD;
      600 mg daily x 17 days, prednisone 5 mg BID; (4b) docetaxel 75mg/m2, pazopanib 800 mg daily x&#xD;
      17 days, (5b) docetaxel 75mg/m2, pazopanib 1000mg daily x 17 days, prednisone 5 mg. If the&#xD;
      investigators see &gt; 1 dose limiting toxicity (DLT) at Dose level 3 then the investigators&#xD;
      would investigate docetaxel 75 mg/m2, pazopanib 600 mg daily, prednisone 5 mg BID (Dose level&#xD;
      3a). If &lt; 1 DLT are seen at Dose level 3 and Pharmacokinetic (PK) analysis is complete and&#xD;
      acceptable, then the investigators will proceed to dose level 4) docetaxel 75 mg/m2,&#xD;
      pazopanib 1000 mg daily, prednisone 5 mg BID.&#xD;
&#xD;
      The investigators will dose escalate in a classic 3+3 design. The maximum tolerated dose&#xD;
      (MTD) will be defined as the highest dose level that does not result in 2 or more dose&#xD;
      limiting toxicities (DLTs). A dose expansion at the MTD of 10-15 patients (up to a total of&#xD;
      36 patients) will be accrued in order to further describe the safety profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Percent of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>15 months</time_frame>
    <description>The primary objective for the phase I study is to assess the safety and tolerability of pazopanib, docetaxel, and prednisone given in combination in patients with metastatic castration resistant prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish the maximum tolerated dose</measure>
    <time_frame>15 months</time_frame>
    <description>Determine the dose levels of pazopanib and docetaxel that are the most tolerated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the optimal dosing schedule</measure>
    <time_frame>15 months</time_frame>
    <description>Establish the optimal dosing schedule for the combination of docetaxel, prednisone and pazopanib</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily pazopanib for Days 1-21 in combination with docetaxel given IV on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily oral administration of pazopanib for Days 3-19 in combination with docetaxel given intravenous administration on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Dose Level &quot;Xa&quot; - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg.</description>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <other_name>Pazopanib (GW786034)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2</description>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Dose Level &quot;Xb&quot; - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg.</description>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
    <other_name>Pazopanib (GW786034)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>5mg Prednisone given twice daily days 1-21.</description>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <arm_group_label>Dose Level &quot;Xa&quot;</arm_group_label>
    <arm_group_label>Dose Level &quot;Xb&quot;</arm_group_label>
    <other_name>Neulasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed carcinoma of the prostate. Histologic evidence may be&#xD;
             confirmed through local or metastatic biopsy review. Non-adenocarcinomas are&#xD;
             permitted.&#xD;
&#xD;
          -  Radiographic evidence of metastatic disease; non-evaluable, bone only metastasis is&#xD;
             permitted.&#xD;
&#xD;
          -  Evidence of disease progression despite castrate levels of testosterone (&lt;50 ng/dl).&#xD;
&#xD;
          -  At the time of screening, at least 2 weeks since prior palliative radiation therapy&#xD;
             and 4 weeks from major surgery, and resolution of all toxic effects of prior therapy&#xD;
             to National Cancer Institute Common Terminology Criteria for Adverse Events&#xD;
             (NCI-CTCAE); version 4.0 Grade &lt; 1.&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Adequate laboratory parameters&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  Written, signed and dated Institutional Review Board (IRB) approved informed consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or active central nervous system metastases&#xD;
&#xD;
          -  The use of immunologic, biologic, or hormonal therapies within 2 weeks of study entry.&#xD;
&#xD;
          -  Major surgery, open biopsy, traumatic injury within 4 weeks of the screening visit&#xD;
&#xD;
          -  Subjects who have not recovered from prior biopsy, surgery, traumatic injury, and/or&#xD;
             radiation therapy.&#xD;
&#xD;
          -  Previous treatment with docetaxel, including in the neo-adjuvant or adjuvant setting&#xD;
&#xD;
          -  Presence of non-healing wound or ulcer&#xD;
&#xD;
          -  Grade 3 or greater hemorrhage within the past month.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  American Heart Association Class 2-4 heart disease or any history of congestive heart&#xD;
             failure with an ejection fraction &lt;40%, recent cardiovascular event (within 12 months)&#xD;
             including unstable angina, any exertional angina, myocardial infarction, exertional or&#xD;
             rest claudication, or stroke/Cerebral Vascular Event/Transient Ischemic Attack.&#xD;
             Patients with known moderate to severe documented carotid or peripheral vascular&#xD;
             disease are excluded. Angioplasty or stenting of coronary or peripheral arteries are&#xD;
             exclusionary if within the past 12 months.&#xD;
&#xD;
          -  Anticoagulation with warfarin (therapeutic doses of warfarin for catheter patency are&#xD;
             permitted up to 2 mg/day). Low molecular weight heparin is permitted.&#xD;
&#xD;
          -  Diabetes mellitus with glycosylated hemoglobin A1c (HbgA1c) &gt; 8% despite therapy&#xD;
&#xD;
          -  Subjects with active autoimmune disorder(s) being treated with systemic&#xD;
             immunosuppressive agents within 4 weeks prior to the screening visit.&#xD;
&#xD;
          -  Active infection(s), active antimicrobial therapy or serious intercurrent illness.&#xD;
&#xD;
          -  Does not agree to use medically acceptable contraceptive methods while on study and&#xD;
             for 3 months after the last dose of pazopanib.&#xD;
&#xD;
          -  Any other major medical or psychiatric illness that, in the investigator's judgment,&#xD;
             will substantially increase the risk associated with the subject's participation in&#xD;
             this study, including inability to absorb oral medications.&#xD;
&#xD;
          -  Known hypersensitivity to any of the components in the docetaxel infusion or other&#xD;
             medical reasons for not being able to receive adequate premedication (for example,&#xD;
             antihistamine or anti-inflammatory agents).&#xD;
&#xD;
          -  CalculatedQT (QTc) interval on baseline EKG &gt; 500milliseconds&#xD;
&#xD;
          -  History or presence of nephrotic syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 12, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Daniel George, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>pazopanib</keyword>
  <keyword>docetaxel</keyword>
  <keyword>metastatic prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

